Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

Monika L. Metzger(St. Jude Children's Research Hospital), Matthew J. Krasin(St. Jude Children's Research Hospital), John T. Lucas(Wake Forest University), Torunn I. Yock(Massachusetts General Hospital), Sarah S. Donaldson(Stanford University), Eric Larsen(University of Massachusetts Chan Medical School), Sandra Luna‐Fineman(Children's Hospital Colorado), Amy L. Billett(Harvard University Press), Jamie E. Flerlage(St. Jude Children's Research Hospital), Nickhill Bhakta(St. Jude Children's Research Hospital), Barry L. Shulkin(St. Jude Children's Research Hospital), Matthew J. Ehrhardt(St. Jude Children's Research Hospital), Pedro de Alarcón(Illinois College), Zhaohua Lu(St. Jude Children's Research Hospital), Melissa M. Hudson(Cincinnati Children's Hospital Medical Center), Chen Li(Hebei General Hospital), Alison M. Friedmann(Harvard University), Michael P. Link(Stanford University), Susan M. Hiniker(Stanford University), Sue C. Kaste(St. Jude Children's Research Hospital), Belinda N. Mandrell(St. Jude Children's Research Hospital)
Journal of Clinical Oncology
April 7, 2021
Cited by 59


Related Papers